These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17301581)

  • 1. Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era.
    Taffé P; Bucher HC; Flepp M; Battegay M
    AIDS; 2007 Feb; 21(4):537-8. PubMed ID: 17301581
    [No Abstract]   [Full Text] [Related]  

  • 2. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?
    Hill A; Miralles D; Vangeneugden T; Lefebvre E
    AIDS; 2007 Jul; 21(12):1651-3. PubMed ID: 17630565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Bani-Sadr F; Goderel I; Morand P; Payan C; Lunel F; Pol S; Perronne C; Carrat F; Cacoub P
    AIDS; 2007 Jul; 21(12):1645-8. PubMed ID: 17630563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective.
    Idoko JA; Agbaji O; Agaba P; Akolo C; Inuwa B; Hassan Z; Akintunde L; Badung B; Muazu M; Danang M; Imade G; Sankale JL; Kanki P
    Int J STD AIDS; 2007 Nov; 18(11):760-3. PubMed ID: 18005510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART.
    Belmonte L; Olmos M; Fanin A; Parodi C; Baré P; Concetti H; Pérez H; de Bracco MM; Cahn P
    AIDS; 2007 Oct; 21(15):2106-8. PubMed ID: 17885303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outbreaks of genital herpes: effects on plasma HIV type 1 viral loads in individuals receiving highly active antiretroviral therapy.
    Lee V; Foley E; Barton SE; Patel R
    J Infect Dis; 2004 Dec; 190(11):2057-8. PubMed ID: 15529276
    [No Abstract]   [Full Text] [Related]  

  • 13. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands.
    Goossens VJ; Wolffs PF; van Loo IH; Bruggeman CA; Verbon A
    AIDS; 2009 Jul; 23(11):1425-9. PubMed ID: 19531930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of anti-HIV-1 chemotherapy in Japan.
    Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing and interpreting HIV noninferiority trials in naive and experienced patients.
    Hill A; Sabin C
    AIDS; 2008 May; 22(8):913-21. PubMed ID: 18453850
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV eradication--facts and fiction].
    Jaeger H; Wolf E
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.